EMA/PE/0000182928
Submitted by Anonymous (not verified) on 2 July 2026 - 16:40
EMA/PE/0000182928
EMEA-003489-PIP01-23
Submitted by Anonymous (not verified) on 2 July 2026 - 16:38
EMEA-003489-PIP01-23
EMEA-003489-PIP02-23
Submitted by Anonymous (not verified) on 2 July 2026 - 16:38
EMEA-003489-PIP02-23
EMEA-003435-PIP02-23
Submitted by Anonymous (not verified) on 2 July 2026 - 16:36
EMEA-003435-PIP02-23
EMA/PE/0000232774
Submitted by Anonymous (not verified) on 2 July 2026 - 16:35
EMA/PE/0000232774
EMA steps up efforts on medicines for women’s health
Submitted by Anonymous (not verified) on 2 July 2026 - 13:30
EMA steps up efforts on medicines for women’s health
Human medicines European public assessment report (EPAR): Xofluza, baloxavir marboxil, Date of authorisation: 07/01/2021, Revision: 10, Status: Authorised
Submitted by Anonymous (not verified) on 2 July 2026 - 13:26
Human medicines European public assessment report (EPAR): Xofluza, baloxavir marboxil, Date of authorisation: 07/01/2021, Revision: 10, Status: Authorised
Human medicines European public assessment report (EPAR): Trimbow, beclometasone,formoterol,glycopyrronium bromide, Date of authorisation: 17/07/2017, Revision: 11, Status: Authorised
Submitted by Anonymous (not verified) on 2 July 2026 - 13:25
Human medicines European public assessment report (EPAR): Trimbow, beclometasone,formoterol,glycopyrronium bromide, Date of authorisation: 17/07/2017, Revision: 11, Status: Authorised
Human medicines European public assessment report (EPAR): Alkindi, hydrocortisone, Date of authorisation: 09/02/2018, Revision: 13, Status: Authorised
Submitted by Anonymous (not verified) on 2 July 2026 - 11:42
Human medicines European public assessment report (EPAR): Alkindi, hydrocortisone, Date of authorisation: 09/02/2018, Revision: 13, Status: Authorised
Declaration of interests: Silvy da Rocha Dias
Submitted by Anonymous (not verified) on 2 July 2026 - 10:56
Declaration of interests: Silvy da Rocha Dias